Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion

Blood Adv. 2020 Jul 14;4(13):2991-2995. doi: 10.1182/bloodadvances.2020001890.

Abstract

  1. Juvenile xanthogranuloma (JXG) usually presents with lesions isolated to the skin; however, aggressive, disseminated forms also occur.

  2. Identification of a novel MRC1-PDGFRB fusion in a child with JXG guided targeted therapy with dasatinib, leading to a dramatic response.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Dasatinib / therapeutic use
  • Family
  • Humans
  • Membrane Glycoproteins
  • Receptor, Platelet-Derived Growth Factor beta* / genetics
  • Receptors, Immunologic
  • Xanthogranuloma, Juvenile* / drug therapy

Substances

  • MRC1 protein, human
  • Membrane Glycoproteins
  • Receptors, Immunologic
  • PDGFRB protein, human
  • Receptor, Platelet-Derived Growth Factor beta
  • Dasatinib